Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Medicinova, Inc. (NASDAQ: MNOV).

Full DD Report for MNOV

You must become a subscriber to view this report.


Recent News from (NASDAQ: MNOV)

MediciNova Announces Opening of Investigational New Drug Application for MN-166 (ibudilast) in Glioblastoma
LA JOLLA, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the Investigational New Drug Application (IND) for MN-...
Source: GlobeNewswire
Date: May, 09 2018 19:00
MediciNova to Present at the UBS Global Healthcare Conference in New York
LA JOLLA, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that MediciNova will present a corporate overview at the UB...
Source: GlobeNewswire
Date: May, 08 2018 19:00
MediciNova Announces Plans to Collaborate with UCLA Researchers in Grant-Funded Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder and Withdrawal
LA JOLLA, Calif., May 07, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it plans to initiate a clinical trial of MN-166 (ibud...
Source: GlobeNewswire
Date: May, 07 2018 19:00
Cirius Therapeutics completes enrollment in mid-stage study of lead candidate in NASH
Privately held Cirius Therapeutics announces that it has reached the enrollment target in a Phase 2b clinical trial, EMMINENCE , assessing lead candidate MSDC-0602K in patients with NASH and liver fibrosis. More news on: Conatus Pharmaceuticals, Galectin Therapeutics, Inc., Navidea Bi...
Source: SeekingAlpha
Date: May, 02 2018 10:47
MediciNova Announces Additional Data from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 70th Annual Meeting
LA JOLLA, Calif., April 26, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), announced that principal investigator Dr. Benjamin Rix Brooks, Director, ...
Source: GlobeNewswire
Date: April, 26 2018 19:00
MediciNova Announces the Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology (AAN) 70th Annual Meeting Plenary Session with Additional Imaging Data
LA JOLLA, Calif., April 24, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Dr. Robert Fox, Staff Neurologist at the Cleveland ...
Source: GlobeNewswire
Date: April, 24 2018 06:30
Q2 2018 Biotech Catalyst Watchlist: Phase 2 Clinical Trials
By Slingshot Insights intern Samuel Jordan We have a full slate of exciting Phase 2 data releases for Q2 2018. This article will focus on four that we think are going to be major catalysts for the companies involved. The Phase 2 data addressed in this article come from trials for Sangamo...
Source: SeekingAlpha
Date: April, 19 2018 12:04
3 Things In Biotech, April 16: Liver, Liver, And More Liver
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace wi...
Source: SeekingAlpha
Date: April, 17 2018 08:00
Your Daily Pharma Scoop: Intercept's OCA, MediciNova In NASH, Pulse Biosciences Data
A nalysis focus: Intercept Intercept Pharmaceuticals ( ICPT ) reported clinical data from a liver biopsy-based substudy from its phase 3 POISE study. The study indicated that long-term OCA treatment in patients with PBC led to reversal or stabilization of fibrosis and cirrhosis. ...
Source: SeekingAlpha
Date: April, 16 2018 08:00
MediciNova's tipelukast shows treatment effect in mid-stage NASH/NAFLD study; shares up 8% premarket
Thinly traded small cap MediciNova (NASDAQ: MNOV ) is up  8%  premarket on light volume in response to its announcement of positive preliminary results from a Phase 2 proof-of-concept clinical trial assessing MN-001 (tipelukast) in NASH and NAFLD patients. The data were presented...
Source: SeekingAlpha
Date: April, 13 2018 07:03

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1710.5010.3910.5010.14109,132
2018-02-2610.9811.0911.1010.60150,505
2018-02-2311.0010.9111.0110.69156,836
2018-02-2210.6010.6210.8610.56106,659
2018-02-2110.9510.6110.9910.61218,029

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-187,83820,89237.5168Short
2018-05-178,66417,67749.0128Short
2018-05-168,32122,91936.3061Short
2018-05-1511,31916,43268.8839Short
2018-05-1410,49922,16947.3589Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on MNOV.


About Medicinova, Inc. (NASDAQ: MNOV)

Logo for Medicinova, Inc. (NASDAQ: MNOV)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $417,460,091 - 05/11/2018
  • Issue and Outstanding: 41,129,073 - 04/24/2018

 


Recent Filings from (NASDAQ: MNOV)

Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: May, 17 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 26 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 26 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 26 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 25 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 21 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 14 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 13 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: February, 08 2018

 

 


Daily Technical Chart for (NASDAQ: MNOV)

Daily Technical Chart for (NASDAQ: MNOV)


Stay tuned for daily updates and more on (NASDAQ: MNOV)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: MNOV)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MNOV is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of MNOV and does not buy, sell, or trade any shares of MNOV. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/